Canbridge Pharmaceuticals Inc
Company Profile
Business description
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Contact
Building 21, No. 388 Xinping Street
Unit 18, 6th Floor, Suzhou Industrial Park
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
100
Stocks News & Analysis
stocks
2 ASX shares to avoid after results
stocks
Strong results from IPO bolter not enough to change our view
stocks
No sign of AI slowdown for Nvidia
Morningstar Investment Ideas
Stocks
ETFs
- Australian ETFs
- Active Australian Equity ETFs
- Passive Australian Equity ETFs
- Emerging Market Equity ETFs
- Sustainable ETFs
- Active Global Equity ETFs
- Passive Global Equity ETFs
- Active Australian Fixed Interest ETFs
- Passive Australian Fixed Interest ETFs
- Active Australian Listed Property ETFs
- Passive Australian Listed Property ETFs
- Active Global Fixed Interest ETFs
- Passive Global Fixed Interest ETFs
- Active Global Infrastructure ETFs
- Passive Global Infrastructure ETFs
- Active Global Property ETFs
- Passive Global Property ETFs
Funds
- Active Australian Equity Funds
- Passive Australian Equity Funds
- Active Global Equity Funds
- Passive Global Equity Funds
- Sustainable Funds
- Emerging Market Equity Funds
- Passive Australian Listed Property Funds
- Active Australian Listed Property Funds
- Passive Global Infrastructure Funds
- Active Global Infrastructure Funds
- Active Global Property Funds
- Passive Global Property Funds
- Active Australian Fixed Interest Funds
- Passive Australian Fixed Interest Funds
- Active Global Fixed Interest Funds
- Passive Global Fixed Interest Funds
Markets
Index
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| All Ordinaries | 8,316.70 | 53.10 | 0.64% |
| CAC 40 | 7,630.95 | 10.00 | -0.13% |
| DAX 40 | 18,906.92 | 5.65 | -0.03% |
| Dow JONES (US) | 41,563.08 | 228.03 | 0.55% |
| FTSE 100 | 8,376.63 | 3.01 | -0.04% |
| HKSE | 17,989.07 | 202.75 | 1.14% |
| NASDAQ | 17,713.62 | 197.19 | 1.13% |
| Nikkei 225 | 38,647.75 | 285.22 | 0.74% |
| NZX 50 Index | 12,447.68 | 94.07 | 0.76% |
| S&P 500 | 5,648.40 | 56.44 | 1.01% |
| S&P/ASX 200 | 8,091.90 | 46.80 | 0.58% |
| SSE Composite Index | 2,842.21 | 19.11 | 0.68% |
Market Movers
Name
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| Aurizon Holdings Ltd AZJ | 3.38 | 0.00 | 0.00% |
| Latin Resources Ltd LRS | 0.20 | 0.01 | -2.44% |
| Red 5 Ltd RED | 0.34 | 0.02 | 6.25% |
| Droneshield Ltd DRO | 1.33 | 0.09 | 7.29% |
| Mesoblast Ltd MSB | 1.03 | 0.08 | 8.42% |
| Spartan Resources Ltd SPR | 1.46 | 0.16 | 12.36% |
| Telstra Group Ltd TLS | 3.93 | 0.02 | 0.51% |
| Pilbara Minerals Ltd PLS | 2.97 | 0.06 | 2.06% |
| Appen Ltd APX | 1.00 | 0.22 | -17.70% |
| South32 Ltd S32 | 3.14 | 0.04 | 1.29% |